Solventum has appointed former Zimmer Biomet executive Rachel Ellingson as chief strategy and corporate development officer.

Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments and regulatory ...

Mizuho raised the firm’s price target on Solventum (SOLV) to $82 from $70 and keeps a Neutral rating on the shares following the Q4 report. The ...

Shares of Solventum Corp. shed 4.42% to $79.75 Friday, on what proved to be an all-around positive trading session for the ...

Solventum Co. (NYSE:SOLV – Get Free Report) has been assigned an average rating of “Hold” from the eleven brokerages that are currently covering the company, MarketBeat.com reports. One research ...

Shares of Solventum jumped Tuesday and led S&P 500 gainers intraday after medical device maker Thermo Fisher Scientific said ...

Solventum (NYSE: SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 ...

(Reuters) -Contract drug manufacturer Thermo Fisher Scientific said on Tuesday it will buy Solventum's purification and ...

Solventum faces significant challenges in its turnaround, including slow-growing core businesses, share loss, and margin ...

Solventum Corp., 3M’s medtech spinoff, has sold its purification and filtration business to Massachussetts-based Thermo ...

Thermo Fisher Scientific agreed to pay about $4.1 billion in cash to acquire Solventum’s purification and filtration business ...

Adjusted free cash flow significantly declined to $92 million from $459 million in Q4 2023. Solventum surpassed fourth-quarter revenue and earnings expectations while facing challenges in segments ...